Hematological Disorders

pharma-news-for-roche-novartis-vertex-telix

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Roche’s Columvi Phase III STARGLO Trial; Novartis’ Fabhalta Latest Data; Vertex’s Alpine Immune Sciences Acquisition; Telix Pharmaceuticals’ TLX101-CDx Fast Track Designation; NovelMed’s NM5072 Orphan Drug Designation

Explore More...
Phase 1b MonumenTAL-2 Study Result

TALVEY’s Versatility Shines: Key Insights from MonumenTAL-2 Study Illuminate Effective Strategies in Relapsed/Refractory Multiple Myeloma

Breakthrough Success: AUGMENT-101 Trial Hits Primary Endpoint with Consistent CR/CRh Rates Across Adult and Pediatric KMT2Ar AML and ALL Cohorts

Phase 3 Results Support D-VRd

DARZALEX FASPRO Quadruplet Regimen Demonstrates Striking Advancements in Treatment Outcomes for Newly Diagnosed Multiple Myeloma Eligible for Transplantation

Phase 3 CARTITUDE-4 Study

Cilta-cel Demonstrates Prolonged and Deep Responses across Advanced Treatment Lines, Signifying Potential in Early Lenalidomide-Refractory Multiple Myeloma

Phase 2 CARTITUDE-2 Trial of Ciltacabtagene Autoleucel

Cilta-Cel’s Prolonged Impact: Deep Responses and Safety Insights from Earlier Lines of Therapy in Multiple Myeloma

Phase 2 ELM-2 Study in Patients with DLBCL

Odronextamab Trial: Striking Response Rates and Enduring Outcomes in High-Risk R/R DLBCL Subgroups

Phase 1/2 BRUIN Study of Pirtobrutinib

Pirtobrutinib Monotherapy: A Promising Beacon of Efficacy and Safety in Relapsed/Refractory Follicular Lymphoma Patients

Phase I/II EPCORE NHL-1 Trial Update

EPCORE NHL-1 Trial Reveals Promising Response Rates for Investigational Follicular Lymphoma Therapy: A Game-Changing Alternative in Focus

Analysis of the Phase 2 PILOT Study

Liso-cel (lisocabtagene maraleucel) Shines in Second-Line, Yielding Long-Lasting Complete Responses for Non-Transplant Eligible LBCL Patients

Liso-cel in TRANSCEND CLL 004: Unprecedented and Sustained Responses with Manageable Safety Profile, Signaling a Promising Advance in Relapsed or Refractory CLL Treatment

Highlight of Liso-cel

Liso-cel Shines in TRANSCEND FL: Impressive Complete Responses, Durable Overall Responses, and Manageable Safety as a Second-Line Treatment for Relapsed Follicular Lymphoma

jaypirca-for-chronic-lymphocytic-leukemia

Eli’s Jaypirca: A Beacon of Success in the BTK Inhibitor Market

unlocking-the-future-of-hematology-ash-2023-preview

Unlocking the Future of Hematology: A Sneak Peek into ASH 2023 Discoveries!

Pharma News for Takeda, AskBio, Bayer, Lipella

Takeda’s ADZYNMA Approved by FDA; AskBio Presents Preliminary Data from Phase I Trial of Gene Therapy for CHF; Bayer’s Aflibercept 8 mg Recommended for Approval in EU; FDA Orphan Drug Designation to MAIA Biotechnology’s THIO; First Patient Dosed in Phase III ProstACT GLOBAL Study; FDA Grants Orphan Designation for Lipella’s LP-310 Drug Candidate

tibsovo-for-myelodysplastic-syndrome-treatment

Servier’s Tibsovo Opens The Door To A New Era In The Battle Against Myelodysplastic Syndromes

aav-gene-therapies-for-hemophilia-b-treatment

AAV Gene Therapies for Hemophilia B Treatment: The Road to a Cure

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader